Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
1999-08-04
2002-02-12
Davenport, Avis M. (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S015800, C514S016700, C514S018700
Reexamination Certificate
active
06346514
ABSTRACT:
The present invention is directed to peptide pharmaceutical compositions and uses thereof, in particular, small peptides including the amino acid sequence, Glx-Lys. These peptide compositions are useful for modulation of the immune system; the treatment of immunodepressed states and of opportunistic infections in immunodepressed states associated with acquired immune deficiency syndrome; treatment of infections caused by bacterial, viral, fungal, and parasitic organisms; augmentation of vaccination response; treatment of atopic states, treatment of anemias; treatment of leukocytic disorders; and the like.
BACKGROUND OF THE INVENTION
A wide variety diseases are caused by abnormalities of the immune system and hematological systems of animals including man. Further, the immune system is required to treat many other diseases. For example, immunodeficiencies such as the acquired immunodeficiency syndrome (AIDS) most commonly cause premature death and disability by making the person susceptible to infections and malignancies. This susceptibility is caused by a weakening of the immune system. Specifically, the HIV virus that causes AIDS attacks and kills T helper cells. Loss of T helper cells compromises the host's ability to fight infections by normal immunological mechanisms. Many types of malignancy are also associated with immunodeficient states suggesting that they are caused by a failure of normal host immune surveillance systems. Many diseases cause secondary immunodeficiency allowing for more rapid progression of the primary disease or the development of secondary diseases. Methods to enhance suppressed immune systems have not achieved high levels of efficacy.
Diseases may also be caused by hyperactivity of the immune system. For example, collagen vascular diseases are associated with immunologically-mediated damage to the host tissue. Such diseases include multiple sclerosis, rheumatoid arthritis and the like. These diseases afflict many individuals and cause significant morbidity and mortality. Treatments generally include immune suppression. Unfortunately, generalized immune suppression often results in increased incidence of infections and malignancies. Therefore, to treat one disease patients are placed at risk for developing other, possibly life threatening, diseases.
Immunological stimulation, even in healthy individuals, may aid in the treatment of several diseases. Infectious diseases may be more effectively treated by stimulation of the immune system. The enhanced immunological response may work with other treatments to eliminate the infection more readily. Also, specific immune stimulation has been shown to reduce tumor size in some malignancies. Also, many drugs used for primary treatment of infections and malignancies have significant side effects. Therefore, it is desirable to reduce the dose of the primary drug whenever possible.
What is needed in the art are compositions and methods for modulating the immune system. Ideally, these compounds and methods would be able to stimulate suppressed or deficient immune systems as well as reduce immune hyperactivity. Also these compounds and methods should act to restore a natural balance to the immune system. Quite surprisingly, the present invention fulfills these and other related needs.
SUMMARY OF THE INVENTION
The present invention provides compositions comprising a peptide having the formula R′-Glx-Glx-Lys-R″ (SEQ ID NO:1) or a pharmaceutically acceptable salt thereof; wherein Glx is Glu or Gln; R′ is H- or a first amino acid sequence having fewer than 7 amino acids; R″ is -H or a second amino acid sequence having fewer than 7 amino acids; and the peptide has a sequence of at least 5 and not more than 9 amino acids. Generally, R′ is H-, Thr-Ala-, Thr-Pro-, Ser-Ala-, Ser-Pro-, Ser-Ser-, Met-Leu-Thr-Ala- (SEQ ID NO:32), or Leu-Thr-Ala-; and R″ is -H, -Ala, -Ala-Ala or -Ala-Val (SEQ ID NOS:2-31). In preferred embodiments, the peptide is L-Thr-L-Pro-L-Glu-L-Glu-L-Lys (SEQ ID NO:33) or L-Thr-L-Ala-L-Glu-L-Glu-L-Lys (SEQ ID NO:34).
Also provided are pharmaceutical preparations comprising a peptide having the formula R′-Glx-Lys-R″ (SEQ ID NO:35) or a pharmaceutically acceptable salt thereof, wherein Glx is Glu or Gln; R′ is H- or a first amino acid sequence having fewer than 7 amino acids; R″ is -H or a second amino acid sequence having fewer than 7 amino acids; and the peptide has a sequence of at least 2 and not more than 9 amino acids; and a physiologically acceptable carrier. In preferred embodiments, the peptide is L-Glu-L-Lys, L-Thr-L-Ala-L-Glu-L-Glu-L-Lys (SEQ ID NO:34) or L-Thr-L-Pro-L-Glu-L-Glu-L-Lys (SEQ ID NO:33).
Methods for using the peptides of the present invention are also provided. These methods include administration of the pharmaceutical preparations of the present invention for immunomodulation of a host's immune system, treatment of infections, treatment of anemias, treatment of atopic states, and treatment of leukocytic disorders.
REFERENCES:
patent: 3803118 (1974-04-01), Bennett et al.
patent: 4002602 (1977-01-01), Goldstein
patent: 4010148 (1977-03-01), Goldstein
patent: 4038282 (1977-07-01), Hirschmann et al.
patent: 4077949 (1978-03-01), Goldstein
patent: 4079127 (1978-03-01), Goldstein et al.
patent: 4116951 (1978-09-01), Wang
patent: 4120951 (1978-10-01), Goldstein
patent: 4133804 (1979-01-01), Bach et al.
patent: 4148788 (1979-04-01), Wang
patent: 4167557 (1979-09-01), Goldstein
patent: 4261886 (1981-04-01), Goldstein et al.
patent: 4264571 (1981-04-01), Goldstein et al.
patent: 4297276 (1981-10-01), Goldstein et al.
patent: 4339427 (1982-07-01), Goldstein et al.
patent: 4353821 (1982-10-01), Birr et al.
patent: 4374828 (1983-02-01), Folkers et al.
patent: 4377511 (1983-03-01), Lopukhin et al.
patent: 4388234 (1983-06-01), Horecker
patent: 4389343 (1983-06-01), Horecker
patent: 4395404 (1983-07-01), Low et al.
patent: 4396605 (1983-08-01), Birr
patent: 4426324 (1984-01-01), Meienhofer
patent: 4427783 (1984-01-01), Newman et al.
patent: 4428938 (1984-01-01), Kisfaludy et al.
patent: 4442031 (1984-04-01), Felix et al.
patent: 4466918 (1984-08-01), Birr et al.
patent: 4470926 (1984-09-01), Birr et al.
patent: 4500450 (1985-02-01), Seipke et al.
patent: 4504415 (1985-03-01), Felix et al.
patent: 4505853 (1985-03-01), Goldstein et al.
patent: 4517119 (1985-05-01), Felix et al.
patent: 4526717 (1985-07-01), Seipke et al.
patent: 4571336 (1986-02-01), Houck et al.
patent: 4599231 (1986-07-01), Milich et al.
patent: 4612365 (1986-09-01), Birr et al.
patent: 4614731 (1986-09-01), Horecker
patent: 4621135 (1986-11-01), Trainin et al.
patent: 4634682 (1987-01-01), Erickson et al.
patent: 4659694 (1987-04-01), Horecker
patent: 4696915 (1987-09-01), Horecker
patent: 4699898 (1987-10-01), Gottlieb
patent: 4711952 (1987-12-01), Kasafirek et al.
patent: 4722999 (1988-02-01), Handschumacher et al.
patent: 4751216 (1988-06-01), Gottlieb
patent: 4753927 (1988-06-01), Hahn
patent: 4814434 (1989-03-01), Goldfarb
patent: 4826680 (1989-05-01), Jaeger
patent: 4904643 (1990-02-01), Brunetti et al.
patent: 4910296 (1990-03-01), Birr et al.
patent: 4983387 (1991-01-01), Goldstein et al.
patent: 5070076 (1991-12-01), Morozov et al.
patent: 5081108 (1992-01-01), Gottlieb
patent: 5093321 (1992-03-01), Gottlieb
patent: 5100663 (1992-03-01), Gottleib
patent: 1 363 801 (1994-08-01), None
patent: 0 164 654 (1985-05-01), None
patent: WO89/06134 (1989-07-01), None
patent: WO93/08816 (1993-05-01), None
Bespalov, et al., Eksp. Oncol, Chem. Abstract No 146389R, 11 (4) 23-6 (Russ.) (Oct. 23, 1989).
Anisimov et al., “Carcinogenesis and Aging,”Mechanisms of Ageing and Development,19:245-258 (1982).
Anisimov et al., “Effect of Low-Molecular-Weight Factors of Thymus and Pineal Gland on Life Span and Spontaneous Tumour Development in Female Mice of Different Age,”Mechanisms of Ageing and Development,49:245-257 (1989).
Belokrylov et al., “A Low-Molecular-Weight Homogeneous Fraction of the Thymus Stimulating Immunogenesis,”Bulletin of Experimental Biology,84(7)56-58
Green Lawrence R.
Ivanov Vadim T.
Khavinson Vladimir K.
Mikhaltsov Alexander N.
Mikhalyova Inessa I.
Cytran Incorporation
Davenport Avis M.
Townsend and Townsend / and Crew LLP
LandOfFree
Pharmaceutical lysine-containing polypeptide compositions... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical lysine-containing polypeptide compositions..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical lysine-containing polypeptide compositions... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2958545